L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy.
It is well known that L-asparaginase (L-Ase) treatment may cause thrombotic events in patients with acute lymphoblastic leukemia (ALL). The mechanism of this effect is not well understood although a reduction in plasma antithrombin III (AT III) levels is observed. In our study, a group of patients treated with L-Ase received AT III concentrates as adjuvant treatment. This adjuvant treatment reduced the levels of plasma D-dimer and thrombin-antithrombin complex, which are considered as early markers of a hypercoagulability state. These preliminary data suggest that large randomized trials will have to be conducted to improve our understanding of the role of AT III concentrates in ALL therapy.
Pogliani
E M
EM
Istituto di Scienze Biomediche dell'Università di Milano, Italy.
Parma
M
M
Baragetti
I
I
Mostarda
G
G
Rivolta
F
F
Maffé
P
P
Corneo
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D013927:Thrombosis / Q000097:blood* / Q000139:chemically induced / Q000517:prevention & control
D000990:Antithrombin III; D001215:Asparaginase